Contributions of hepatic and intestinal pathways to cholesterol excretion

肝脏和肠道途径对胆固醇排泄的贡献

基本信息

  • 批准号:
    9447975
  • 负责人:
  • 金额:
    $ 46.96万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-09-13 至 2022-07-31
  • 项目状态:
    已结题

项目摘要

7. Project Summary The elimination of excess cholesterol from the body is essential in maintaining homeostasis and opposing the development of a number of metabolic diseases, most notably atherosclerotic cardiovascular disease. Classically, cholesterol elimination is thought to be accomplished by hepatic metabolism of cholesterol to bile acids and the secretion of both bile acids and cholesterol in the bile. However, under a number of conditions in which biliary secretion of cholesterol is compromised fecal excretion is maintained, indicating the presence of a non-biliary, alternate pathway. Previously published and preliminary studies demonstrate that the proximal small intestine is capable of secreting cholesterol and that the rate of intestinal cholesterol secretion increases when biliary cholesterol secretion is reduced. The hypothesis of this proposal is that transintestinal cholesterol elimination (TICE) is regulated by biliary cholesterol output, by plasma lipoprotein donors, and by an enterohepatic signaling axis involving bile acids. To date, the contribution of the intestine to cholesterol excretion has largely been inferred by calculating differences in cholesterol concentrations in bile among strains of mice or in response to pharmacological agents relative to the changes in fecal neutral sterols. We have developed a novel surgical procedure to simultaneously measure rates of biliary and intestinal cholesterol secretion in mice. This will allow us to address, for the first time, the relative rates of biliary and intestinal cholesterol secretion, track the delivery of cholesterol from plasma lipoproteins to both the hepatic and intestinal pathway, and better understand how the intestine adapts to alterations in biliary cholesterol secretion. The aims are to: I) determine the impact of biliary cholesterol secretion on intestinal cholesterol secretion rates, II) determine the lipoprotein donors to both the biliary and intestinal pathway under conditions of high and low biliary cholesterol secretion, and III) determine the impact of bile acid signaling in the intestine on hepatic and intestinal cholesterol secretion. The accomplishment of these aims will further our understanding of the intestine as a regulator of cholesterol homeostasis and identify novel regulators of intestinal cholesterol secretion that may be targeted to promote cholesterol excretion and the removal of excess cholesterol from the body.
7.项目摘要 从体内消除多余的胆固醇对于维持体内平衡和 对抗许多代谢性疾病的发展,尤其是动脉粥样硬化 心血管疾病传统上,胆固醇的消除被认为是通过肝脏来完成的。 胆固醇代谢为胆汁酸以及胆汁中胆汁酸和胆固醇的分泌。 然而,在胆固醇的胆汁分泌受到损害的许多情况下, 维持排泄,表明存在非胆汁替代途径。先前 已发表的和初步的研究表明,近端小肠能够 分泌胆固醇和肠道胆固醇分泌率增加时,胆汁 胆固醇分泌减少。这项提议的假设是, 胆固醇清除(TICE)受胆汁胆固醇排出量、血浆脂蛋白供体和 涉及胆汁酸的肝肠信号轴。到目前为止,肠道对 胆固醇排泄主要是通过计算胆固醇浓度的差异来推断的 小鼠品系之间的胆汁中或对药物的反应相对于粪便中的变化 中性固醇我们已经开发了一种新的外科手术方法, 胆汁和肠胆固醇分泌。这将使我们能够第一次解决 胆固醇和肠胆固醇分泌的相对速率,跟踪胆固醇从 血浆脂蛋白的肝脏和肠道途径,并更好地了解如何 肠道适应胆汁胆固醇分泌的改变。目的是:(一)确定影响 胆汁胆固醇分泌对肠道胆固醇分泌率的影响,II)测定脂蛋白 在高胆固醇和低胆固醇条件下,胆和肠途径的供体 III)确定肠中胆汁酸信号传导对肝和肠分泌的影响, 胆固醇分泌这些目标的实现将进一步加深我们对 肠作为胆固醇体内平衡调节剂并鉴定新的肠调节剂 胆固醇分泌,可能有针对性地促进胆固醇排泄和清除多余的 体内的胆固醇。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Gregory A Graf其他文献

Gregory A Graf的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Gregory A Graf', 18)}}的其他基金

Don S. Fredrickson Lipid Research Conference
唐·S·弗雷德里克森脂质研究会议
  • 批准号:
    10752509
  • 财政年份:
    2023
  • 资助金额:
    $ 46.96万
  • 项目类别:
The Don S. Fredrickson Lipid Research Conference
唐·弗雷德里克森脂质研究会议
  • 批准号:
    10539150
  • 财政年份:
    2022
  • 资助金额:
    $ 46.96万
  • 项目类别:
Contributions of hepatic and intestinal pathways to cholesterol excretion
肝脏和肠道途径对胆固醇排泄的贡献
  • 批准号:
    9750695
  • 财政年份:
    2017
  • 资助金额:
    $ 46.96万
  • 项目类别:
Contributions of hepatic and intestinal pathways to cholesterol excretion
肝脏和肠道途径对胆固醇排泄的贡献
  • 批准号:
    10222657
  • 财政年份:
    2017
  • 资助金额:
    $ 46.96万
  • 项目类别:
Contributions of Hepatic and Intestinal Pathways to Cholesterol Excretion
肝脏和肠道途径对胆固醇排泄的贡献
  • 批准号:
    10656625
  • 财政年份:
    2017
  • 资助金额:
    $ 46.96万
  • 项目类别:
The role of hepatic insulin resistance on SR-BI dependant HDL cholesterol uptake
肝脏胰岛素抵抗对 SR-BI 依赖性 HDL 胆固醇摄取的作用
  • 批准号:
    9235659
  • 财政年份:
    2013
  • 资助金额:
    $ 46.96万
  • 项目类别:
The role of hepatic insulin resistance on SR-BI dependant HDL cholesterol uptake
肝脏胰岛素抵抗对 SR-BI 依赖性 HDL 胆固醇摄取的作用
  • 批准号:
    8613990
  • 财政年份:
    2013
  • 资助金额:
    $ 46.96万
  • 项目类别:
The role of hepatic insulin resistance on SR-BI dependant HDL cholesterol uptake
肝脏胰岛素抵抗对 SR-BI 依赖性 HDL 胆固醇摄取的作用
  • 批准号:
    8737894
  • 财政年份:
    2013
  • 资助金额:
    $ 46.96万
  • 项目类别:
Regulation of the ABCG5 ABCG8 Sterol Transporter
ABCG5 ABCG8 甾醇转运蛋白的调节
  • 批准号:
    8274829
  • 财政年份:
    2009
  • 资助金额:
    $ 46.96万
  • 项目类别:
Regulation of the ABCG5 ABCG8 Sterol Transporter
ABCG5 ABCG8 甾醇转运蛋白的调节
  • 批准号:
    7881405
  • 财政年份:
    2009
  • 资助金额:
    $ 46.96万
  • 项目类别:

相似海外基金

Development of Antisense Oligonucleotides to Regulate Gamma' Fibrinogen Levels
开发反义寡核苷酸来调节γ纤维蛋白原水平
  • 批准号:
    10759950
  • 财政年份:
    2023
  • 资助金额:
    $ 46.96万
  • 项目类别:
Inducing H3F3A exon skipping with antisense oligonucleotides as an approach to treat diffuse intrinsic pontine glioma
用反义寡核苷酸诱导 H3F3A 外显子跳跃作为治疗弥漫性内源性脑桥胶质瘤的方法
  • 批准号:
    10677284
  • 财政年份:
    2023
  • 资助金额:
    $ 46.96万
  • 项目类别:
Inducing PKM splice-switching with antisense oligonucleotides as an approach to treat hepatocellular carcinoma
用反义寡核苷酸诱导 PKM 剪接转换作为治疗肝细胞癌的方法
  • 批准号:
    10464020
  • 财政年份:
    2022
  • 资助金额:
    $ 46.96万
  • 项目类别:
Promoting adult hippocampal neurogenesis using antisense oligonucleotides as an Alzheimer's disease therapy
使用反义寡核苷酸促进成人海马神经发生作为阿尔茨海默氏病的治疗
  • 批准号:
    10484703
  • 财政年份:
    2022
  • 资助金额:
    $ 46.96万
  • 项目类别:
Strategy for specific delivery of antisense oligonucleotides to T cells
将反义寡核苷酸特异性递送至 T 细胞的策略
  • 批准号:
    10547347
  • 财政年份:
    2022
  • 资助金额:
    $ 46.96万
  • 项目类别:
Metabolism of Antisense Oligonucleotides and other Polyanions in Liver
反义寡核苷酸和其他聚阴离子在肝脏中的代谢
  • 批准号:
    10806783
  • 财政年份:
    2022
  • 资助金额:
    $ 46.96万
  • 项目类别:
Metabolism of Antisense Oligonucleotides and other Polyanions in Liver
反义寡核苷酸和其他聚阴离子在肝脏中的代谢
  • 批准号:
    10689248
  • 财政年份:
    2022
  • 资助金额:
    $ 46.96万
  • 项目类别:
Metabolism of Antisense Oligonucleotides and other Polyanions in Liver
反义寡核苷酸和其他聚阴离子在肝脏中的代谢
  • 批准号:
    10501862
  • 财政年份:
    2022
  • 资助金额:
    $ 46.96万
  • 项目类别:
Inducing PKM splice-switching with antisense oligonucleotides as an approach to treat hepatocellular carcinoma
用反义寡核苷酸诱导 PKM 剪接转换作为治疗肝细胞癌的方法
  • 批准号:
    10623180
  • 财政年份:
    2022
  • 资助金额:
    $ 46.96万
  • 项目类别:
Identifying binding partners, biological substrates and antisense oligonucleotides regulating expression of short and long ACE2.
识别调节短和长 ACE2 表达的结合伴侣、生物底物和反义寡核苷酸。
  • 批准号:
    BB/V019848/1
  • 财政年份:
    2021
  • 资助金额:
    $ 46.96万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了